:format(webp)/cdn.mskdoctors.com/storage/2026/7/YjVRrObruXhFRSj4s2XzPrviUN6lGG71.jpg)
Cartilage Specialist or General Orthopaedic SurgeonFocal cartilage damage—treated with progressive repair techniques from injections to cell-based therapy—warrants a cartilage specialist. Widespread arthritis, fractures, or joint replacement require a general orthopaedic surgeon. Damage type and location, not pain severity, determine which specialist is appropriate.Focal cartilage damage—treated with progressive repair techniques from injections to cell-based therapy—warrants a cartilage specialist. Widespread arthritis, fractures, or joint replacement require a general orthopaedic surgeon. Damage type and location, not pain severity, determine which specialist is appropriate.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/KwXLz2jRfwRD3qHMy8DHg5EOnfWclZIb.jpg)
Questions that reveal ChondroFiller provider expertiseChondroFiller triggers cartilage repair through a structural scaffold—unlike hyaluronic acid, which lubricates, or corticosteroids, which reduce inflammation. The UK competency gap is wider than for standard injections; correct patient selection demands imaging knowledge and clinical precision.ChondroFiller triggers cartilage repair through a structural scaffold—unlike hyaluronic acid, which lubricates, or corticosteroids, which reduce inflammation. The UK competency gap is wider than for standard injections; correct patient selection demands imaging knowledge and clinical precision.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/gsAUDRVQLunD0FcY4ym5CZ9Bm37CFOyy.jpg)
When cartilage repair makes sense before knee replacementTotal knee replacement achieves over 90% long-term success, yet patients under 55 face substantially higher revision risk within 20 years. For focal cartilage damage in the mid-40s, repair offers a joint-preservation pathway suited to this earlier disease stage—provided defect size and patient profile meet defined clinical criteria.Total knee replacement achieves over 90% long-term success, yet patients under 55 face substantially higher revision risk within 20 years. For focal cartilage damage in the mid-40s, repair offers a joint-preservation pathway suited to this earlier disease stage—provided defect size and patient profile meet defined clinical criteria.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/FK644oTRDklVIZLpnja41H3Urci859jL.jpg)
ChondroFiller IKDC and MOCART scoresChondroFiller patients' functional-outcome scores (IKDC) gain approximately 30 points within 12 months, rising from ~48 to ~80, whilst structural MRI (MOCART) markers advance from 65 to 81–84 — dual tracks converging on tissue repair and restored joint function.ChondroFiller patients' functional-outcome scores (IKDC) gain approximately 30 points within 12 months, rising from ~48 to ~80, whilst structural MRI (MOCART) markers advance from 65 to 81–84 — dual tracks converging on tissue repair and restored joint function.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/J20dyyiCwCNYJA27kKufzruIBZeitWiP.jpg)
OCA or MACI for large knee cartilage defectsWhen subchondral bone is damaged alongside large knee cartilage defects, OCA — a single-stage transplant of donor bone and cartilage — is the preferred choice; MACI, which implants cultured cells, cannot restore bone stock once lost.When subchondral bone is damaged alongside large knee cartilage defects, OCA — a single-stage transplant of donor bone and cartilage — is the preferred choice; MACI, which implants cultured cells, cannot restore bone stock once lost.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/2hoqnEBJW6PS9qANeFgmU7H7tZecPFZC.jpg)
Why ChondroFiller requires a specialist injection pathwayChondroFiller, a collagen matrix, self-polymerises within three to five minutes of injection; needle placement under ultrasound guidance must therefore be exact, as repositioning becomes impossible once gelation begins and structural repair unfolds over six to twelve months.ChondroFiller, a collagen matrix, self-polymerises within three to five minutes of injection; needle placement under ultrasound guidance must therefore be exact, as repositioning becomes impossible once gelation begins and structural repair unfolds over six to twelve months.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/jsvrgfCOH4IBtCsmXXnshr2LWJGubdnf.jpg)
MACI versus microfracture for knee cartilage repairMACI outperforms microfracture for knee cartilage defects of 3 cm² or larger, according to the SUMMIT randomised trial, which found significantly greater improvements in pain and function at two years that persisted through five years.MACI outperforms microfracture for knee cartilage defects of 3 cm² or larger, according to the SUMMIT randomised trial, which found significantly greater improvements in pain and function at two years that persisted through five years.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/hni8MzqBb5F58Pemnb9wF3BSQI0fYlj6.jpg)
ChondroFiller injection vs surgery for focal knee cartilageAn ultrasound-guided collagen injection activates the joint's own regenerative cells to repair focal knee cartilage defects; 70–85% of treated patients report meaningful symptom relief within three to five years.An ultrasound-guided collagen injection activates the joint's own regenerative cells to repair focal knee cartilage defects; 70–85% of treated patients report meaningful symptom relief within three to five years.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/92K6tqyBnZDrB97bjQM5FimjqPsDB7mw.jpg)
How long ChondroFiller results lastChondroFiller's collagen scaffold biodegrades within 6–24 months, yet provides lasting clinical benefit by recruiting the patient's own cells to form repair tissue; 70–85% of well-selected patients maintain meaningful symptom relief at three to five years.ChondroFiller's collagen scaffold biodegrades within 6–24 months, yet provides lasting clinical benefit by recruiting the patient's own cells to form repair tissue; 70–85% of well-selected patients maintain meaningful symptom relief at three to five years.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/ZSqxnuCC3vLEtfjeh2qqQ3EKNznGabau.jpg)
Is OATS knee surgery worth itCartilage damage beyond a certain point cannot self-repair. OATS transplants healthy cartilage plugs to replace it, with 85–93% achieving clinical success and improvements sustained at ten and twenty years, though 10–15% experience persistent donor-site pain.Cartilage damage beyond a certain point cannot self-repair. OATS transplants healthy cartilage plugs to replace it, with 85–93% achieving clinical success and improvements sustained at ten and twenty years, though 10–15% experience persistent donor-site pain.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/UY0InSBaoOinSJHR9T3qmZrV7DMIQOXA.jpg)
ChondroFiller vs PRP for focal cartilage defectsFocal cartilage defects and diffuse cartilage loss are different problems requiring different solutions. ChondroFiller, a collagen scaffold, physically occupies and stabilises focal voids, recruiting repair cells over 12–24 months. PRP releases growth factors to reduce inflammation but cannot fill a structural gap. Imaging reveals which mechanism addresses the patient's underlying…Focal cartilage defects and diffuse cartilage loss are different problems requiring different solutions. ChondroFiller, a collagen scaffold, physically occupies and stabilises focal voids, recruiting repair cells over 12–24 months. PRP releases growth factors to reduce inflammation but cannot fill a structural gap. Imaging reveals which mechanism addresses the patient's underlying problem.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/nJpuPYmYxVIJuCuke5TmcJtXlcYJxImS.jpg)
ChondroFiller or Arthrosamid for your kneeChondroFiller repairs focal cartilage defects via a collagen scaffold, and Arthrosamid provides cushioning by integrating into the synovial lining — because they target different anatomical structures, the MRI scan, not patient preference, determines which injection is appropriate.ChondroFiller repairs focal cartilage defects via a collagen scaffold, and Arthrosamid provides cushioning by integrating into the synovial lining — because they target different anatomical structures, the MRI scan, not patient preference, determines which injection is appropriate.
